

DEALS AND SUITS

Eli Health closes \$17 million Series A to fuel launch of hormone-monitoring tech

On June 10, 2025, Montréal-based [Eli Health](#) announced it had secured \$17 million (US\$12 million) in Series A funding to support the launch of its flagship hormone-monitoring technology product. The round was supported by new investors Montréal-based Accelia Capital and Vancouver's Telus Global Ventures (after a prior investment via Telus' Pollinator Fund for Good), plus US-based Rocana Ventures and Swizzle Ventures, Japan's Nextblue, and Brazil's IKJ Capital, among others.

After investing nearly six years in research and development (R&D) and closing a major financing for a Canadian tech startup focused on women's health, Eli Health claims it has reached commercial readiness for its initial two hormones and is ready to bring its offering to market.

BLG represented Accelia Capital led by [Francis Lussier](#).